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ABSTRAK
Latar belakang: risiko non-alcoholic fatty liver disease (NAFLD) meningkat pada pasien dengan diabetes 
melitus (DM) tipe 2. Prevalensi dan faktor-faktor yang berhubungan dengan peningkatan risiko NAFLD pada 
populasi DM di Indonesia belum pernah diteliti. Profil derajat fibrosis pada populasi ini juga masih belum 
diketahui. Tujuan penelitian ini mengetahui perbedaan profil pasien DM dengan atau tanpa NAFLD serta 
derajat fibrosisnya. Metode: penelitian dikerjakan secara potong lintang terhadap pasien DM tipe 2 dewasa 
yang berobat di poliklinik endokrin metabolik RSCM. Pengambilan sampel dilakukan secara konsekutif. Data 
yang dikumpulkan mencakup usia, lama diabetes, indeks masa tubuh (IMT), lingkar pinggang, kadar HDL, 
trigliserida, dan HbA1C. Ultrasonografi abdomen dikerjakan pada semua pasien untuk menentukan adanya 
NAFLD. Pasien dengan NAFLD lalu menjalani pemeriksaan elastografi transien untuk menilai derajat fibrosis. 
Uji Chi Square atau Fischer’s-Exact digunakan untuk analisis bivariat dan regresi logistik digunakan untuk 
analisis multivariat. Hasil: sebanyak 186 pasien dianalisis dalam studi ini, dengan 84 pasien (45,2%) terbukti 
mengalami NAFLD. Elastografi transien berhasil dikerjakan pada 68 pasien NAFLD, dengan 17 pasien (25,0%) 
terbukti mengalami fibrosis berat. Analisis univariat menunjukan perbedaan signifikan IMT (PR=1,878; 95% 
CI= 1,296-2,721; p<0,001) dan lingkar pinggang (PR=2,368; 95% CI= 1,117-5,017; p=0,018) antara kelompok 
NAFLD dan tidak. Namun pada uji multivariat, IMT merupakan satu-satunya faktor yang berbeda bermakna 
antara kedua kelompok (OR=2,989; 95%CI=1,625-5,499; p<0,001). Kesimpulan: prevalensi NAFLD pada 
pasien DM tipe 2 di RSCM mencapai 45,2%, dengan 25,0% di antaranya mengalami fibrosis berat. IMT 
merupakan satu-satunya komponen dalam studi ini yang berhubungan dengan kejadian NAFLD.
Kata kunci: non-alcoholic fatty liver disease (NAFLD), diabetes melitus, fibrosis.
ABSTRACT
Background: the risk of Non-Alcoholic Fatty Liver Disease (NAFLD) is increasing in patients with type-2 
diabetes. Prevalence and factors related to the increased risk of NAFLD in diabetic patients in Indonesia has 
never been studied before. Data regarding the profile of fibrosis in the population has also been unknown. This 
study aimed to identify the difference on the profile of diabetic patients with and without NAFLD as well as the 
degree of fibrosis. Methods: the study was conducted using a cross-sectional method in type-2 diabetic patients 
who were treated at the outpatient clinic of endocrinology and metabolic division in Cipto Mangunkusumo 
Hospital. Sampling was done consecutively. Collected data comprised of age, duration of diabetes, body 
mass index (BMI), waist circumference, HDL, triglyceride, and HbA1C levels. Abdominal ultrasonography 
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was conducted for all patients to determine the presence of NAFLD. Patients with NAFLD were subsequently 
underwent transient elastography in order to assess their degree of liver fibrosis. Chi-square or Fisher’s-Exact 
tests were used for bivariate analysis and logistic regression was used for multivariate analysis. Results: as 
many as 186 patients were analyzed in the study and 84 patients (45.2%) were demonstrated to have NAFLD. 
Transient elastography examinations were carried out in 68 patients and 17 patients (25.0%) were found with 
severe fibrosis. Univariate analysis showed significant differences on BMI (PR=1.878; 95%CI= 1.296-2.721; 
p<0.001) and waist circumference (PR=2.368; 95%CI= 1.117-5.017; p=0.018) between patients with and 
without NAFLD. However, the multivariate test showed that BMI was the only factor that had a significance 
difference between both groups (OR=2.989; 95%CI=1.625-5.499; p<0.001). Conclusion: prevalence of NAFLD 
among type-2 diabetic patients in Cipto Mangunkusumo Hospital has reached 45.2% and 25.0% among them 
had severe fibrosis. BMI is the only factor found to be associated with the occurrence of NAFLD.
Keywords: non-alcoholic fatty liver disease (NAFLD), diabetes melitus, fibrosis.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is 
a spectrum of disease, characterized by steatosis 
or the formation of fat in the liver. In Western 
countries, NAFLD has been regarded as the 
most common form of chronic liver disease. The 
prevalence of NAFLD in general population of 
the USA is 24%-51%.1,2 While in Indonesia, one 
study has revealed that fatty liver affected 30% 
of the population.3 As a part of disease spectrum, 
NAFLD is a process which consists of 2 stages: 
Non-Alcoholic Fatty Liver (NAFL) and Non-
Alcoholic Steatohepatitis (NASH). Ultimately 
about 10%-29% of patients will eventually 
develop risk of cirrhosis in 10 years; while 
4%-27% of them will lead to hepatocellular 
carcinoma.2
The association between NAFLD and 
metabolic disease has been studied for decades. 
The available data show that the prevalence 
of NAFLD may reach 69% among patients 
with type-2 diabetes mellitus (DM); while the 
prevalence of diabetes mellitus in NAFLD 
population may reach 33-50%. Those studies 
were conducted in the USA, where most of 
the population involved is Caucasian. The 
prevalence of NAFLD patients with DM and 
obesity may reach 70%.4
Age, duration of DM, Body Mass Index 
(BMI), waist circumference, the serum levels 
of HbA1C, LDL, and triglyceride are factors 
that have been widely accepted to be affecting 
the NAFLD incidence in DM patients, which 
has been oftenly discussed in overseas studies.5 
However, there has been no data in Indonesia 
on the prevalence of NAFLD and its associated 
factors in DM population. Data about the severity 
of fibrosis stage in Indonesian population has 
been not available as well. Lack of data may 
lead to the lack of awareness among medical 
workers on the urgency of NAFLD triage in 
DM population. Therefore, our study was aimed 
to evaluate the burden of NAFLD among DM 
population in Indonesia.
METHODS
The study was a cross-sectional study among 
adult patients with type-2 diabetes mellitus, who 
were registered at the Endocrinology Outpatient 
Clinic in Cipto Mangunkusumo Hospital. 
Consecutive sampling was performed. Patients 
who had given their informed consent went 
through history taking and physical examination 
to collect data of age, duration of DM, anti-
diabetic and anti-cholesterol medications, BMI, 
waist circumference, HDL, triglycerides and 
HbA1C levels. Ultrasonography was performed 
using the instrument of USG GE Healthcare 
Logiq P6. Diagnosis of NAFLD was made when 
increased echogenicity of liver parenchymal 
compared to renal cortex in the same window 
were found. Transient elastography examination 
using the instrument of Echosens Fibroscan 502 
Touch was then performed in NAFLD patients to 
determine the degree of fibrosis including mild 
moderate and severe fibrosis with a limit of 9.6 
kPa. The collected sample was then categorized 
based on the presence or absence of  NAFLD as 
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the dependent variable and based on age (<40 or 
≥40 years), duration of DM (<5 or ≥5 year), BMI 
(<25.0 or ≥25.0), waist circumference (<100 
or ≥100 cm for male and 90 cm for female), 
HbA1C level (<7.0 or ≥7.0), HDL level (above 
40 for male and 50 for female without medication 
or  below 40 for male and 50 for female with 
or without medication) and triglycerides level 
(below 150 mg/dL without medication or above 
150 mg /dL with or without treatment), which 
served  as independent variables. Chi-square 
or Fischer’s exact test was used for bivariate 
analysis and logistic regression was used for 
multivariate analysis.
By compiling data from literatures, we 
found that minimum sample size to evaluate 
the prevalence of NAFLD in DM patients was 
83 subjects, while the minimum sample size to 
examine the factors associated with NAFLD 
incidence was 152 subjects.
RESULTS
We recruited 191 patients in the study. As 
many as 5 patients had met the exclusion criteria 
resulted in only 186 subjects included in data 
analysis. Among them, 84 patients (45.2%) in 
our study had been demonstrated of developing 
NAFLD, while 16 subjects of NAFLD patients 
were unable to undergo transient elastography. 
Most of the subjects in our study were over 
40 years old with a median age of 58 years. 
The proportion of female to male patients was 
relatively balanced. Most of the patients had 
suffered from DM of more than 5 years, with 
a median of 96 months. Data of BMI showed a 
relatively balanced result on the proportion of 
obese to non-obese patients; while data of waist 
circumference demonstrated that there were a 
high proportion of patients with central obesity 
(83.3%). Mean waist circumference was high 
(94 cm).  Most of the patients also showed a high 
level of triglycerides (83.3%) and a low level of 
HDL (84.4%) or they were taking medications in 
order to keep those parameters within the normal 
limits. Only 34.4% of patients had HbA1C 
level below 7.0% (mean value of 7.45%). Basic 
subject characteristics can be seen in Table 1.
Univariate analysis has shown that there 
was no significant correlation on age, duration 
Tabel 1. Subject’s characteristics
Variables Value
NAFLD, n (%)
 - Yes 84 (45.2)
 - No 102 (54.8)
Sex, n (%)
 - Male 82 (44.1)
 - Female 104 (55.9)
Age (years), n (%)
 - <40 12 (6.5)
 - ≥40 174 (93.5)
BMI (kg/m2), n (%)
 - <25 82 (44.1)
 - ≥25 104 (55.9)
Waist circumference (cm), n (%)
 - Normal 31 (16.7)
 - Increased 155 (83.3)
Male
 - Normal 25 (30.5)
 - Increased 57 (69.5)
Female
 - Normal 6 (5.8)
 - Increased 98 (94.2)
Duration of DM (months), n (%)
 - <5 years 72 (38.7)
 - ≥5 years 114 (61.3)
HDL (mg/dL), n (%)
 - Normal 29 (15.6)
 - Low 157 (84.4)
Male
 - Normal 16 (19.5)
 - Increased 66 (80.5)
Female 51 (8-91)
 - Normal 13 (12.5)
 - Increased 91 (87.5)
Triglycerides (mg/dL), n (%)
 - Normal 31 (16.7)
 - High 155 (83.3)
HbA1C (%), n (%)
 - <7.0 64 (34.4)
 - ≥7.0 122 (65.6)
Degree of Fibrosis (in NAFLD patients)
 - F0-F2 (Mild) 51 (75.0)
 - F3-F4 (Severe) 17 (25.0)
of DM, triglycerides, HDL and HbA1C levels 
between NAFLD patients and non-NAFLD 
patients. We found significant correlations only 
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for the BMI variable (PR=1.878; 95% CI=1.296-
2.271; p<0.001) and waist circumference 
(PR=2.368; 95% CI=1.117-5.017; p=0.018). 
Complete results of univariate analysis on factors 
associated with NAFLD incidence in our study 
can be seen in Table 2.
The obtained results using multivariate 
analysis showed that BMI was the only factor 
associated with NAFLD incidence in DM 
patients with odd ratio of (OR) 2.989 and 
CI 1.625 - 5.499. The results of the logistic 
regression can be seen in Table 3.
To evaluate the degree of fibrosis in DM 
patients with NAFLD, we performed transient 
elastography in patients with NAFLD. As many 
as 16 patients were unable to undergo the test; 
therefore, a total of 68 patients were evaluated. 
Among them, there were 17 patients (25.0%) 
who were in severe fibrosis stage; while 51 
patients (75.0%) had mild fibrosis or no fibrosis 
at all. The descriptions of subject characteristics 
based on their degree of fibrosis are shown in 
Table 4.
DISCUSSION
This study found that the prevalence of 
NAFLD in type-2 diabetes mellitus population 
was 45.2%, which was higher than the results 
in Hasan et al study that was conducted among 
general population in Indonesia (30%). However, 
our result is lower than the result obtained by 
Lesmana et al6 (51%), which was also conducted 
among general population in Indonesia.3 Our 
results are consistent with results of other 
studies, which were conducted among type-2 
diabetes mellitus population. Data of Western 
population has demonstrated that the prevalence 
of NAFLD in diabetes mellitus patients may 
reach 69%;1 while data from Malaysia and 
Nigeria have shown the rate of 49.2% and 
16.7% respectively.7,8 Different background of 
the subjects was assumed to affect our results 
compared to other studies. NAFLD was known 
to be associated with sedentary life style, which 
is primarily found in developed countries.9
A study among general population conducted 
by Lesmana et al6 has shown that age is one of 
Table 2. Analysis on factors associated with the incidence of NAFLD
Variables non-NAFLD n (%)
NAFLD 
n (%) PR (95% CI) p
Age 1.647 (0.514-5.280) 0.395
 - <40 8 (7.8) 4 (4.8) 
 - ≥40 94 (92.2) 80 (95.2)
BMI 1.878 (1.296-2.721) <0.001
 - <25 57 (55.9) 25 (29.8) 
 - ≥25 45 (44.1) 59 (70.2)
Waist Circumference 2.368 (1.117-5.017) 0.018
 - Normal 23 (22.5) 8 (9.5) 
 - Increased 79 (77.5) 76 (90.5)
Duration of  DM 0.737 (0.513-1.058) 0.097
 - <5 years 34 (33.3) 38 (45.2) 
 - ≥ 5 years 68 (66.7) 46 (54.8)
HDL 1.830 (0.880-3.804) 0.096
 - Normal 20 (19.6) 9 (80.4) 
 - Low 82 (10.7) 75 (89.3)
Triglycerides 1.304 (0.672-2.529) 0.429
 - Normal 19 (18.6) 12 (14.3) 
 - High 83 (81.4) 72 (85.7)
HbA1C 1.285 (0.852-1.937) 0.226
 - <7.0 39 (38.2) 25 (29.8) 
 - ≥7.0 63 (61.8) 59 (70.2)
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Table 3. Logistic regression on factors associated with the incidence of NAFLD
Variables Significance (p) Odd Ratio (OR) 95% CI
Initial variables in the 
analysis 
BMI 0.019 2.283 1.146-4.708
Waist circumference 0.396 1.536 0.571-4.130
Duration of DM 0.123 0.603 0.318-1.147
HDL 0.327 1.574 0.636-3.897
HbA1C 0.116 1.702 0.877-3.302
End Result BMI <0.001 2.989 1.625-5.499
Table 4. The profile of subject characteristics of NAFLD patients based on the degree of fibrosis
Variables F0-F2 (mild to moderate) F3-F4 (severe)
Sex, n (%)
 - Male 18 (35.5) 8 (47.1)
 - Female 33 (64.7) 9 (52.9)
Age (years), n (%)
 - <40 4 (7.8) 0 (0)
 - ≥40 47 (92.2) 17 (100)
BMI (kg/m2), n (%)
 - <25 13 (25.5) 5 (29.4)
 - ≥25 38 (74.5) 12 (70.6)
Waist circumference (cm), n (%)
 - Normal 3 (5.9) 3 (17.6)
 - Increased 48 (94.1) 14 (82.4)
Duration of DM (years), n (%)
 - <5 years 25 (49.0) 6 (35.3)
 - ≥5 years 26 (51.0) 11 (64.7)
HDL (mg/dL), n (%)
 - Normal 4 (7.8) 2 (11.8)
 - Low 47 (92.2) 15 (88.2)
Triglycerides (mg/dL), n (%)
 - Normal 6 (11.8) 3 (17.6)
 - High 45 (88.2) 14 (82.4)
HbA1C (%), n (%)
 - <7.0 18 (35.3) 2 (11.8)
 - ≥7.0 33 (64.7) 15 (88.2)
the predictors for NAFLD. Another review by 
Seto et al10 has also suggested that age is one 
of the factors to increase the risk of NAFLD 
among general population in Asia. However, 
another study by Almobarak11 in DM patients 
had shown that there was no correlation between 
age and NAFLD incidence. Similar results have 
also been found in our study in which the age 
has no association with the incidence of NAFLD 
(p=0.335). Most of patients, in both groups of 
NAFLD and non-NAFLD population, suffered 
from DM for more than 5 years; however, there 
was no significant difference between both 
groups. It indicates that the process of NAFLD 
is not associated with the duration of DM. The 
available literatures explain that the process of 
NAFLD might have occurred long before DM 
had been diagnosed.12
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Most of the patients in our study, either those 
with NAFLD or without NAFLD, were found to 
have central obesity; however, higher incidence 
of obesity was found in NAFLD population 
(p=0.018). Nevertheless, in multivariate analysis, 
we found that there was larger number of 
obesity measured by BMI in NAFLD population 
compared to non-NAFLD subjects (70.2% 
vs. 44.1%, OR 2.989; 95% CI 1.625-5.499; 
p<0.001). A study by Trovato et al, which 
involved 532 NAFLD patients and 667 patients 
in the control group, has successfully shown that 
there was a correlation between high BMI and 
the incidence of NAFLD.13 Meanwhile, a study 
by Wang et al has shown that the prevalence of 
NAFLD was increased in the group with higher 
BMI.14
Similar to central obesity, most patients in 
our study had similar parameters of metabolic 
syndrome regardless the presence or the 
absence of NAFLD. There was no difference 
found between both groups in regard to HDL, 
Triglyceride and HbA1C levels in our study. A 
similar study was performed in 2008 by Leite 
et al.5 The results were also similar to ours, in 
which that both blood glucose control and HDL 
were not associated with the increased risk of 
NAFLD in DM patients. The most prominent 
NAFLD indicator in this study was BMI (OR= 
7.1; 95% CI=3.0-17.0). Such finding is consistent 
with our study. Unlike our results, the data from 
DM population in Nigeria has demonstrated 
a correlation between NAFLD in DM with 
central obesity and low HDL level. On the 
other hand, the researchers had also found that 
there was no association between triglycerides 
level and NAFLD.8 Another study conducted in 
Caucasian population with DM has shown that 
higher waist circumference and low level of HDL 
were two predictors of NAFLD in DM patients. 
Nevertheless, the same study has also revealed 
that there was no association between HbA1C 
and Triglyceride with NAFLD incidence.15 The 
contradictive results have indicated the fact that 
there are a lot of unidentified factors underlying 
NAFLD incidence in patients with diabetes 
mellitus.
Results obtained from our study that shows 
no correlation between general parameters of 
metabolic syndromes and NAFLD incidence 
in DM patients is definitely contrary to many 
literatures.6,16 In spite of that, all previous studies 
had been focusing on the correlation in general 
population instead of DM patient. If we perform 
the evaluation only using descriptive method, 
the results obtained in our study may have been 
consistent with previous studies, i.e. there is a 
high incidence rate of metabolic syndrome in 
NAFLD patients. If it is compared to normal 
population, the result would show significant 
difference. However, in our study, we found 
that the increased incidence rate of metabolic 
syndrome could also be found in DM patients 
without NAFLD. It may cause a significant 
difference in BMI; while not being significant 
in waist circumference parameter.
The mechanism that leads to disturbances 
of metabolic parameters in general population 
with NAFLD is activated by DM; therefore, the 
presence of NAFLD does not show different 
characteristics in this population. Recent 
literature reviews have also mentioned that there 
has been no study that could explain the causal 
correlation between metabolic syndrome and 
NAFLD.17 We found a relatively high proportion 
of patients with central obesity (83.3%), even 
in the non-NAFLD population; while the 
proportion of patients with increased BMI was 
not found as high as those with increased waist 
circumference.
Our study found the incidence of severe 
fibrosis in 25% of patients with NAFLD. The 
rate is higher than result of a study conducted in 
Sudan showing that severe fibrosis only found 
in 14.3% of the diabetes mellitus population 
with NAFLD.11 However, study to examine the 
degree of fibrosis in patients with NAFLD is still 
considered rare. The available studies are mostly 
conducted in general population; therefore, 
result of our study is one of few data that assess 
the degree of fibrosis performed in Type 2 DM 
patients.
A study by Kwok et al18 has shown increased 
rate of cirrhosis as much as 20.6% in DM 
patients with NAFLD. The rate is lower than 
what our finding. However in the study, 
transient elastography was performed in all 
DM population with only 72.8% of them had 
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NAFLD. Patients with severe fibrosis in the 
study shared the same characteristics with those 
in our study in terms of age, duration of DM, 
BMI, waist circumference, HDL and HbA1C 
levels. The only different characteristic with 
our population was the triglycerides parameter.
Kwok18 has also suggested that the increased 
rate of cirrhosis in type-2 DM adult population 
is affected by longer DM duration, higher 
BMI, increased ALT, increased ratio of urinary 
albumin: creatinin levels and low HDL levels. 
The overseas studies so far have not set any 
agreement regarding which metabolic parameter 
that could predict the severity of fibrosis in DM 
patients with NAFLD. It is also supported by the 
fact that neither literature could find the causality 
between fibrosis and metabolic syndrome.19
The advantages of our study were that study 
provides the first data of prevalence and fibrosis 
profile of DM population in Indonesia. Moreover, 
the evaluated variables in the study were those 
that are routinely examined in DM patients. 
However, the study has some limitations, which 
include the cross-sectional design and therefore, 
it cannot describe the causality and in addition, 
the diagnosis of NAFLD in our study was made 
by using USG, which is not a gold standard 
parameter for NAFLD diagnosis. The study has 
already met the minimum requirement of sample 
size as well as covered the accessible and target 
population, therefore, the internal and external 
validation is relatively good and the result of the 
study could be well-generalized.
CONCLUSION
From the study, it can be concluded that 
the prevalence of NAFLD in adult patients 
with type-2 DM who seek treatment in Cipto 
Mangunkusumo Hospital is 45.2% and severe 
fibrosis is found in 25.0%  among them. BMI is 
the only component in our study that has shown 
an association with the incidence of NAFLD in 
type-2 DM patients. Other factors such as  age, 
waist circumference, duration of DM, HDL, 
triglyceride and HbA1C levels do not show any 
significant association.
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